<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017247</url>
  </required_header>
  <id_info>
    <org_study_id>0308-19-RMB</org_study_id>
    <nct_id>NCT04017247</nct_id>
  </id_info>
  <brief_title>Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor</brief_title>
  <official_title>A Comparison Between Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare 2 treatment modalities. One group will receive the routine protocol of
      intermittent pitocin induction for 6 hours and the second group will receive continous
      pitocin infusion.

      The primary aim is to observe which protocol leads to the fastest delivery and evaluate the
      time in each group from induction to delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At enrollment, after consenting to participate in the study, patients will be assigned
      randomly to either routine oxytocin (intermittent) treatment or continuous oxytocin
      treatment.

      Both groups will follow the institutional oxytocin protocol. The primary dose of oxytocin is
      2.0 mU/min, with an incremental increase by 5.0 mU/min every 30 minutes, until 40.0 mU/min,
      tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation &gt;
      6 cm). Women will be continuously monitored to fetal heart rate while oxytocin is
      administered.

      In the intermittent group, oxytocin will be discontinued after 6-8 hours if the patient does
      not go into active labor in that period of time. The second course of oxytocin will be
      renewed after 8-12 hours. In the continuous group, women will receive a continuous oxytocin
      infusion until delivery, unless there is an indication to stop the infusion, including;
      category II fetal tracing, uterine tachysystole (an average of more than 5 contractions in 10
      minutes for more than 30 minutes).

      During oxytocin infusion, sodium levels will be monitored every four hours. In cases where
      the maternal sodium is below 125 mmol/L oxytocin should be stopped. The decision regarding
      further oxytocin administration should be made following assessment of the woman's clinical
      condition and circumstances after discussion with a consultant obstetrician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery within 24 hours</measure>
    <time_frame>from admission up to 24 hours postpartum</time_frame>
    <description>The percentage of women delivering within 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>latent phase of labor.</measure>
    <time_frame>from admission up to 24 hours postpartum</time_frame>
    <description>Length of latent phase of labor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>active phase of labor.</measure>
    <time_frame>from admission up to 24 hours postpartum</time_frame>
    <description>Length of active phase of labor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>caesarian deliveries</measure>
    <time_frame>from admission up to 24 hours postpartum</time_frame>
    <description>The rate of caesarian deliveries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>instrumental deliveries</measure>
    <time_frame>from admission up to 24 hours postpartum</time_frame>
    <description>The rate of instrumental deliveries.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Induced; Birth</condition>
  <arm_group>
    <arm_group_label>Intermittent treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of oxytocin for 6 hours at a time until patient delivers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continous treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of oxytocin continuously from patient admission until patient delivers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intermittent oxytocin Infusion</description>
    <arm_group_label>Intermittent treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Continous oxytocin Infusion</description>
    <arm_group_label>Continous treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with a singleton pregnancy that are admitted for induction or augmentation of
             labor.

          2. Women at gestational age 370/7 or more.

          3. Vertex presentation.

        Exclusion Criteria:

          1. Age under 18 or over 45.

          2. High order gestation.

          3. Women with contraindication for vaginal delivery.

          4. Active labor.

          5. Women with a uterine scar.

          6. Multiparity(&gt; 5 deliveries).

          7. Documented fetal anomalies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Lauterbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roy Lauterbach, MD</last_name>
    <phone>972-52-9432416</phone>
    <email>r_lauterbach@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Lauterbach, MD</last_name>
      <phone>0529432416</phone>
      <email>r_lauterbach@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

